HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The adrenergic receptor agonist, clonidine, potentiates the anti-parkinsonian action of the selective kappa-opioid receptor agonist, enadoline, in the monoamine-depleted rat.

Abstract
1. The treatment of Parkinson's disease relies predominantly upon dopamine replacement therapy, usually with l-dihydroxyphenylalanine (L-DOPA). However, side-effects of long-term treatment, such as L-DOPA-induced dyskinesias can be more debilitating than the disease itself. Non-dopaminergic treatment strategies might therefore be advantageous. 2. The aim of this study was to investigate the potential anti-parkinsonian efficacy of the kappa-opioid receptor agonist, enadoline, and the alpha-adrenoreceptor agonist, clonidine, both alone or in combination, in the reserpine-treated rat model of Parkinson's disease. 3. Rats were treated with reserpine (3 mg kg-1), and experiments carried out 18 h later, at which time they exhibited profound akinesia (normal animals 1251+/-228 mobile counts h-1, reserpine-treated animals 9+/-2 mobile counts h-1). Both enadoline and clonidine increased locomotion in reserpine-treated rats in a dose-dependent manner. The maximum locomotor-stimulating effect of enadoline alone was seen at a dose of 0.2 mg kg-1 (208+/-63 mobile counts h-1). The maximum effect of clonidine was seen at a dose of 2 mg kg-1 (536+/-184 mobile counts h-1). 4. Co-administration of enadoline (0.1 mg kg-1) and clonidine (0.01 - 0.1 mg kg-1) at sub-threshold doses, synergistically increased locomotion. 5. The synergistic stimulation of locomotion in the reserpine-treated rat involved activation of kappa-opioid receptors and a combination of both alpha1 and alpha2-adrenoreceptors. 6. The results presented suggest a need for further studies on the potential of stimulating kappa-opioid and/or alpha-adrenoreceptors as a therapy for Parkinson's disease. Furthermore, the studies may offer potential mechanistic explanations of the ability of alpha2-adrenergic receptor antagonist to reduce L-DOPA-induced dyskinesia in Parkinson's disease.
AuthorsM P Hill, J M Brotchie
JournalBritish journal of pharmacology (Br J Pharmacol) Vol. 128 Issue 7 Pg. 1577-85 (Dec 1999) ISSN: 0007-1188 [Print] England
PMID10602339 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Adrenergic alpha-Agonists
  • Adrenergic alpha-Antagonists
  • Antiparkinson Agents
  • Benzofurans
  • Biogenic Monoamines
  • Drug Combinations
  • Narcotic Antagonists
  • Pyrrolidines
  • Receptors, Opioid, kappa
  • Yohimbine
  • norbinaltorphimine
  • Naltrexone
  • Reserpine
  • enadoline
  • Clonidine
  • Prazosin
Topics
  • Adrenergic alpha-Agonists (pharmacology)
  • Adrenergic alpha-Antagonists (pharmacology)
  • Animals
  • Antiparkinson Agents (pharmacology)
  • Benzofurans (pharmacology)
  • Biogenic Monoamines (metabolism)
  • Clonidine (pharmacology)
  • Disease Models, Animal
  • Drug Combinations
  • Drug Synergism
  • Locomotion (drug effects)
  • Male
  • Naltrexone (analogs & derivatives, pharmacology)
  • Narcotic Antagonists (pharmacology)
  • Parkinson Disease, Secondary (chemically induced, drug therapy, metabolism)
  • Prazosin (pharmacology)
  • Pyrrolidines (pharmacology)
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, Opioid, kappa (agonists)
  • Reserpine (toxicity)
  • Yohimbine (pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: